Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis

Journal of Neuroimmunology

Volumn 254, Issue 1-2, 2013, Pages 117-124

  Begum Haque, Sakhina ^a   Christy, Marc ^a   Wang, Yan ^a   Kasper, Eli ^a   Ochoa Reparaz, Javier ^a   Smith, Jacqueline Y ^a   Haque, Azizul ^a   Kasper, Lloyd H ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Chemokines; Dendritic cells; EAE; GA; IL 10; Osteopontin

Indexed keywords

CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLATIRAMER; INTERLEUKIN 10; INTERLEUKIN 17; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MYELOID DIFFERENTIATION FACTOR 88; OSTEOPONTIN; RANTES; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TOLL LIKE RECEPTOR 9;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG ACTIVITY; FEMALE; MOUSE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BRAIN; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; INTERLEUKIN-17; LYMPH NODES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; OSTEOPONTIN; PEPTIDES; SPLEEN; TOLL-LIKE RECEPTORS;

EID: 84871686022     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.10.003     Document Type: Article

References (51)

1. Aharoni R., Teitelbaum D., Arnon R., Sela M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:634-639.
2. Akira S., Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004, 4:499-511.
3. Arnon R., Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(SUPPL. 2):14593-14598.
4. Arnon R., Aharoni R. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate. J. Neural Transm. 2009, 116:1443-1449.
5. Arnon R., Sela M. Immunomodulation by the copolymer glatiramer acetate. J. Mol. Recognit. 2003, 16:412-421.
6. Begum-Haque S., Sharma A., Kasper I.R., Foureau D.M., Mielcarz D.W., Haque A., Kasper L.H. Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2008, 204:58-65.
7. Begum-Haque S., Sharma A., Christy M., Lentini T., Ochoa-Reparaz J., Fayed I.F., Mielcarz D., Haque A., Kasper L.H. Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2010, 219:47-53.
8. Begum-Haque S., Christy M., Ochoa-Reparaz J., Nowak E.C., Mielcarz D., Haque A., Kasper L.H. Augmentation of Regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate. J. Neuroimmunol. 2011, 232:136-144.
9. Bettelli E., Pagany M., Weiner H.L., Linington C., Sobel R.A., Kuchroo V.K. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J. Exp. Med. 2003, 197:1073-1081.
10. Blanchette F., Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J. Neurol. 2008, 255(SUUPL. 1):26-36.
11. Carty M., Bowie A.G. Evaluating the role of Toll-like receptors in diseases of the central nervous system. Biochem. Pharmacol. 2011, 81:825-837.
12. Chabas D., Baranzini S.E., Mitchell D., Bernard C.C., Rittling S.R., Denhardt D.T., Sobel R.A., Lock C., Karpuj M., Pedotti R., Heller R., Oksenberg J.R., Steinman L. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001, 294:1731-1735.
13. Chen M., Chen G., Nie H., Zhang X., Niu X., Zang Y.C., Skinner S.M., Zhang J.Z., Killian J.M., Hong J. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS. Eur. J. Immunol. 2009, 39:2525-2536.
14. Chiocchetti A., Indelicato M., Bensi T., Mesturini R., Giordano M., Sametti S., Castelli L., Bottarel F., Mazzarino M.C., Garbarini L., Giacopelli F., Valesini G., Santoro C., Dianzani I., Ramenghi U., Dianzani U. High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation. Blood 2004, 103:1376-1382.
15. Cho H.J., Cho H.J., Kim H.S. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr. Atheroscler. Rep. 2009, 11:206-213.
16. Comabella M., Pericot I., Goertsches R., Nos C., Castillo M., Blas Navarro J., Rio J., Montalban X. Plasma osteopontin levels in multiple sclerosis. J. Neuroimmunol. 2005, 158:231-239.
17. Dimitrova P., Ivanovska N. Influence of leflunomide on gastrointestinal Candida albicans infection induced in naive and arthritic newborn mice. Int. Immunopharmacol. 2006, 6:1682-1689.
18. Ford C., Goodman A.D., Johnson K., Kachuck N., Lindsey J.W., Lisak R., Luzzio C., Myers L., Panitch H., Preiningerova J., Pruitt A., Rose J., Rus H., Wolinsky J. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult. Scler. 2010, 16:342-350.
19. Glabinski A.R., Tuohy V.K., Ransohoff R.M. Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis. Neuroimmunomodulation 1998, 5:166-171.
20. Greter M., Heppner F.L., Lemos M.P., Odermatt B.M., Goebels N., Laufer T., Noelle R.J., Becher B. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 2005, 11:328-334.
21. Gur C., Karussis D., Golden E., Doron S., Ilan Y., Safadi R. Amelioration of experimental colitis by Copaxone is associated with class-II-restricted CD4 immune blocking. Clin. Immunol. 2006, 118:307-316.
22. Hohlfeld R., Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(SUPPL. 2):14599-14606.
23. Hur E.M., Youssef S., Haws M.E., Zhang S.Y., Sobel R.A., Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat. Immunol. 2007, 8:74-83.
24. Jansson M., Panoutsakopoulou V., Baker J., Klein L., Cantor H. Cutting edge: Attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J. Immunol. 2002, 168:2096-2099.
25. Jee Y., Piao W.H., Liu R., Bai X.F., Rhodes S., Rodebaugh R., Campagnolo D.I., Shi F.D., Vollmer T.L. CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. Clin. Immunol. 2007, 125:34-42.
26. Kala M., Rhodes S.N., Piao W.H., Shi F.D., Campagnolo D.I., Vollmer T.L. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp. Neurol. 2010, 221:136-145.
27. Kazanecki C.C., Uzwiak D.J., Denhardt D.T. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J. Cell. Biochem. 2007, 102:912-924.
28. Kennedy K.J., Strieter R.M., Kunkel S.L., Lukacs N.W., Karpus W.J. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1. J. Neuroimmunol. 1998, 92:98-108.
29. Marta M., Andersson A., Isaksson M., Kampe O., Lobell A. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2008, 38:565-575.
30. Miller S.D., McMahon E.J., Schreiner B., Bailey S.L. Antigen presentation in the CNS by myeloid dendritic cells drives progression of relapsing experimental autoimmune encephalomyelitis. Ann. N. Y. Acad. Sci. 2007, 1103:179-191.
31. Murugaiyan G., Mittal A., Weiner H.L. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J. Immunol. 2008, 181:7480-7488.
32. Murugaiyan G., Mittal A., Weiner H.L. Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:11495-11500.
33. Nikoopour E., Schwartz J.A., Singh B. Therapeutic benefits of regulating inflammation in autoimmunity. Inflamm. Allergy Drug Targets 2008, 7:203-210.
34. O'Regan A., Berman J.S. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int. J. Exp. Pathol. 2000, 81:373-390.
35. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., Wang Y., Hood L., Zhu Z., Tian Q., Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 2005, 6:1133-1141.
36. Pasare C., Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv. Exp. Med. Biol. 2005, 560:11-18.
37. Prinz M., Garbe F., Schmidt H., Mildner A., Gutcher I., Wolter K., Piesche M., Schroers R., Weiss E., Kirschning C.J., Rochford C.D., Bruck W., Becher B. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J. Clin. Invest. 2006, 116:456-464.
38. Quesniaux V., Fremond C., Jacobs M., Parida S., Nicolle D., Yeremeev V., Bihl F., Erard F., Botha T., Drennan M., Soler M.N., Le Bert M., Schnyder B., Ryffel B. Toll-like receptor pathways in the immune responses to mycobacteria. Microbes Infect. 2004, 6:946-959.
39. Racke M.K., Drew P.D. Toll-like receptors in multiple sclerosis. Curr. Top. Microbiol. Immunol. 2009, 336:155-168.
40. Renkl A.C., Wussler J., Ahrens T., Thoma K., Kon S., Uede T., Martin S.F., Simon J.C., Weiss J.M. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood 2005, 106:946-955.
41. Schrempf W., Ziemssen T. Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun. Rev. 2007, 6:469-475.
42. Shinohara M.L., Lu L., Bu J., Werneck M.B., Kobayashi K.S., Glimcher L.H., Cantor H. Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat. Immunol. 2006, 7:498-506.
43. Shinohara M.L., Kim J.H., Garcia V.A., Cantor H. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 2008, 29:68-78.
44. Teitelbaum D., Aharoni R., Klinger E., Kreitman R., Raymond E., Malley A., Shofti R., Sela M., Arnon R. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies. Ann. N. Y. Acad. Sci. 2004, 1029:239-249.
45. Tomizawa T., Kaneko Y., Kaneko Y., Saito Y., Ohnishi H., Okajo J., Okuzawa C., Ishikawa-Sekigami T., Murata Y., Okazawa H., Okamoto K., Nojima Y., Matozaki T. Resistance to experimental autoimmune encephalomyelitis and impaired T cell priming by dendritic cells in Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 mutant mice. J. Immunol. 2007, 179:869-877.
46. Vogt M.H., Floris S., Killestein J., Knol D.L., Smits M., Barkhof F., Polman C.H., Nagelkerken L. Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J. Neuroimmunol. 2004, 155:155-160.
47. Weber M.S., Prod'homme T., Youssef S., Dunn S.E., Rundle C.D., Lee L., Patarroyo J.C., Stuve O., Sobel R.A., Steinman L., Zamvil S.S. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 2007, 13:935-943.
48. Weiner H.L. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J. Neurol. 2008, 255(SUPPL. 1):3-11.
49. Weiner H.L. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann. Neurol. 2009, 65:239-248.
50. Wiesemann E., Klatt J., Sonmez D., Blasczyk R., Heidenreich F., Windhagen A. Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive T cells. J. Neuroimmunol. 2001, 119:137-144.
51. Zozulya A.L., Reinke E., Baiu D.C., Karman J., Sandor M., Fabry Z. Dendritic cell transmigration through brain microvessel endothelium is regulated by MIP-1alpha chemokine and matrix metalloproteinases. J. Immunol. 2007, 178:520-529.